Who Funds This Category, and on What Terms

Most people writing a plan for an anaesthesia monitoring business start with the market section. That is the wrong end. The capital structure determines which market you can credibly serve, so this guide starts where the money starts.

The medtech venture market tightened sharply between 2024 and 2026. Total medtech venture funding reached roughly USD 11.3 billion in 2025, but seed and Series A companies took only about USD 1.9 billion of that across 113 rounds, and later-stage rounds absorbed close to 69% of all capital raised (Cure Medtech Funding Tracker, 2026). Round sizes compressed in step: the 2026 year-to-date median round sits near USD 20 million against USD 35 million in the equivalent 2025 period and USD 60 million in 2024 (New Market Pitch, 2026).

Read that as a filter rather than a closed door. Capital has not left the category; it has moved behind evidence. A monitoring device with a named predicate, a bench dataset and a costed conformity plan now raises at a stage where, three years ago, a rendering and a clinical advisory board were enough.

Typical instruments by stage

• Pre-seed, $150K–$600K: founder capital, angel syndicate, clinician-investor rounds out of the department the idea came from. Deliverable is a bench prototype and a predicate shortlist.
• Seed, $1M–$4M: the dominant band for device seed rounds. Deliverable is design freeze plus a verification plan with named test houses.
• Series A, $5M–$15M: investors at this stage expect first-in-human data or an FDA submission in flight, plus a reimbursement and market-access position.
• Non-dilutive: Innovate UK and NIHR i4i grants in the UK, NIH SBIR Phase I and II in the US. A Phase I SBIR is small relative to the programme cost but it buys a 510(k)-relevant dataset without equity.
• Debt and asset finance: only realistic once there is a shipped product. Demo-fleet and tooling finance is the common first debt line.

SBA 7(a) for the US distribution or assembly route

Founders often assume SBA lending is closed to medical device businesses. It is not, but it only works for the part of the business that looks like a conventional company. The SBA approved 70,242 7(a) loans worth a combined $31.1 billion in FY2024, across every sector (SBA 7(a) programme data, FY2024). The relevant classification here is NAICS 334510, Electromedical and Electrotherapeutic Apparatus Manufacturing, for which the SBA size standard is 1,250 employees (IBISWorld NAICS 334510). Practically every entrant in this niche sits comfortably inside that definition, so size is never the blocker.

What is the blocker is the use of funds. A 7(a) lender will finance inventory, premises, assembly equipment, service vans and working capital. It will not finance a speculative clinical programme, and it will not underwrite a company whose only asset is an unapproved design. So the common structure is a split: equity or grant money carries the device through clearance, and a 7(a) facility funds the commercial build-out once the product exists and has invoices behind it. Say that explicitly in the funding section of your plan. Lenders respond well to a founder who has already drawn the line themselves.

One more structural point. Pure distribution businesses in this category are considerably more bankable than manufacturers, because they have receivables, inventory and a short cash cycle. If your plan is to distribute two established brands into ambulatory surgery centres while developing your own module in parallel, write it as two business units with two funding stories. Our market research and content service builds exactly that split for the plans we write.

Where the Money Sits in 2026

Published sizings for this category disagree, and the disagreement is informative rather than embarrassing. Mordor Intelligence puts the global anaesthesia monitoring devices market at USD 3.2 billion in 2026, growing at a 9.86% CAGR to USD 5.12 billion by 2031 (Mordor Intelligence, 2026). Towards Healthcare sizes 2025 at USD 3.17 billion and projects USD 7.86 billion by 2035 at 9.5% (Towards Healthcare, 2025), while Precedence Research models the same horizon at USD 8.89 billion (Precedence Research, 2025).

The gap comes from scope. Narrow definitions count only the monitoring hardware; wider ones fold in agent-gas analysers, neuromuscular transmission modules and in some cases the monitoring component of integrated anaesthesia workstations. State in your plan which definition you have adopted and which report you are anchoring to. An investor who has read three of these reports will notice if you have quietly picked the largest number.

Vendor concentration is lower than it looks

On 2024 revenue share, GE HealthCare held roughly 11% of the category, Medtronic plc 9%, Drägerwerk AG & Co. KGaA 7%, Mindray Medical International 6% and Koninklijke Philips N.V. 5% (Mordor Intelligence, 2024 share data). That is around 38% held by the top five, leaving roughly 62% spread across regional vendors, specialists and private-label suppliers. Compare that with imaging or surgical robotics and the category looks unusually open.

The strategic positions differ in a way worth naming in a competitor section. GE HealthCare, Medtronic and Philips push all-in-one workstations and bundle cybersecurity patching and remote fleet management to win hospital-wide contracts. Masimo competes from the other direction, embedding algorithms into narrow monitors that integrate with existing anaesthesia information management systems. Mindray and Edan Medical compete on installed cost and have taken significant share in procurement-led markets. Each of those is a different competitive threat, and a plan that lists all five under one heading has not done the work.

Size the market from the installed base, not from the top down

The number that actually governs your forecast is how many anaesthetising locations you can physically reach with the sales model you can afford. In the US, ASC Data counted 12,294 total ambulatory surgery centres as of Q2 2025, of which 6,504 were Medicare-certified, running more than 18,000 operating rooms between them, with 168 newly certified ASCs entering the Medicare programme during 2024 and a steady 1.6% annual growth rate (ASC Data Industry Overview, August 2025). The average ASC runs 2.89 operating rooms and covers 2.84 specialties.

That gives you a bottom-up frame a lender can audit. Pick a state, count the Medicare-certified ASCs, multiply by average operating rooms, apply a replacement-cycle assumption of seven to ten years for capital monitors, and you have a serviceable obtainable market you can defend line by line. If you are also sizing the hospital theatre segment, treat it separately: procurement cycles, capital committee structures and tender mechanics are nothing alike.

The UK route runs through framework agreements

In the UK, almost all volume flows through national framework agreements rather than direct trust-by-trust selling. The NHS Supply Chain Patient Monitoring Equipment framework was launched with anticipated expenditure of around £166 million in its first 24 months and an estimated £332 million across its 48-month term, running from 8 June 2024 to 7 June 2028 with a 24-month extension option (NHS Supply Chain contract launch brief). A separate national framework for anaesthesia machines, ventilators, neonatal equipment and phototherapy devices carries an estimated total value of £260 million excluding VAT (Find a Tender, 2025).

Scotland runs its own route. NHS National Services Scotland awarded a four-year, £36 million framework for patient monitors, anaesthetic machines, ventilators and ECG across multiple suppliers including AC Cossor & Son Surgical, Draeger Medical, Edan Medical and Fukuda Denshi, each taking an £11 million share (Bidstats award notice, 2024). The commercial implication for a new entrant is blunt: frameworks reopen on multi-year cycles, so your UK launch plan has to be timed against a tender calendar you do not control. Build the interim revenue from private hospital groups, veterinary theatres and dental sedation clinics, and say so in the plan rather than leaving a two-year hole.

What It Costs to Reach First Revenue

There is no single startup cost for an anaesthesia monitoring business because there are three genuinely different businesses hiding under the same search term. Across all three the realistic band is $180,000 to $2.4 million in the US, or £140,000 to £1.8 million in the UK. Within that band:

• Regional distribution of existing brands: $180,000–$450,000 (£140K–£350K). Inventory, demo fleet, two field reps, one service engineer.
• ODM or private-label programme: $400,000–$900,000 (£320K–£700K). You own the brand, regulatory file and service obligation; the contract manufacturer owns the platform.
• Own-IP device carried through 510(k): $900,000–$2.4 million (£700K–£1.8M). Engineering, verification, clinical evidence, QMS and conformity in three jurisdictions.

The regulatory line items, named and priced

This is where most plans in this niche go wrong, so these numbers are worth stating precisely rather than as a percentage allowance.

• FDA 510(k) submission fee, FY2026: $26,067 standard, or $6,517 if you hold a current Small Business Determination — a 75% reduction (Federal Register, FY2026 MDUFA rates)
• FDA annual establishment registration, FY2026: $11,423, with no small-business rate, although MDUFA V now allows a hardship waiver for qualifying small businesses after initial registration (FDA MDUFA fees)
• ISO 13485 quality system build plus first certification audit: $15,000–$40,000 for a company under about 25–30 staff, with certification-body audit fees of $10,000–$20,000 for initial certification and $2,000–$15,000 for annual surveillance (ISO 13485 cost and timeline guide, 2026)
• MHRA registration: no upfront registration fee, but an annual fee of £300 per GMDN Level 2 category from 1 April 2026 (UK MHRA device registration, 2026)
• UK Responsible Person and three-year UK market access, Class IIb: roughly $9,000–$32,000 all in, excluding MHRA government fees (UK registration cost guide, 2026)
• EU MDR notified body, Class IIb, application to first certificate: EUR 50,000–150,000 for a small or mid-sized manufacturer (CE marking cost breakdown, 2026)
• India CDSCO MD-15 import licence, Class C: USD 3,000 per site plus USD 1,500 per device (CDSCO registration and licence fees, 2025)

Add those up for a single device going to the US, UK, EU and India and the pure conformity bill before any engineering is roughly $110,000 to $270,000. That is the number to carry into your use-of-funds table, not the $26,067 headline.

Engineering and evidence

• Electronics, firmware and sensor engineering to design freeze: $250,000–$900,000 (£200K–£700K). Analogue front-end for a biopotential or optical sensor is the cost driver.
• Verification and validation: $90,000–$260,000 (£70K–£200K), covering IEC 60601-1 general safety, 60601-1-2 electromagnetic compatibility, 60601-1-8 alarm systems, 60601-2-49 multifunction patient monitors, IEC 62304 software lifecycle and ISO 10993 biocompatibility on any patient-contact sensor.
• Clinical and usability evidence for a depth-of-anaesthesia claim: $120,000–$500,000 (£95K–£400K). A basic vital-signs claim is far cheaper; an index claim is not.
• Contract manufacturer tooling, first article and pilot build: $80,000–$300,000 (£65K–£240K).
• Product liability and clinical trial insurance, year one: $18,000–$60,000 (£14K–£48K).
• Demo fleet of 8–15 units at cost for hospital and ASC evaluations: $40,000–$150,000 (£32K–£120K). Evaluation units are a cost of sale in this category, not a marketing extra.

People, and what they actually cost

The US Bureau of Labor Statistics put the median annual wage for bioengineers and biomedical engineers at $109,370 in May 2025, with the top decile above $168,180 — and within navigational, measuring, electromedical and control instruments manufacturing specifically, the figure rises to $130,340 (BLS Occupational Outlook Handbook, 2025). On the commercial side, medical device sales representatives averaged total compensation of around $157,251 per year in December 2025 data, with the interquartile range running from roughly $121,005 to $209,019.

Two consequences for the plan. First, a four-engineer team is a $450,000 to $520,000 annual line before employer costs, which is usually more than the founder's first draft assumes. Second, field sales in this category is expensive and commission-heavy, so a direct sales model only works above a certain deal density. Below that, a dealer network at 18–30% gross margin is the cheaper path to the same operating rooms.

Hardware, Consumables and the Real Revenue Engine

Most guides on this topic stop at the capital price of a monitor. The number that actually drives this business is the consumable attach rate, and a plan without an explicit attach-rate assumption will not survive a second investor meeting.

Price points to build the model on

• Basic multi-parameter anaesthesia monitor: $3,500–$9,000 (£2,800–£7,200) per unit
• Integrated anaesthesia workstation monitor: $14,000–$38,000 (£11,200–£30,400)
• Depth-of-anaesthesia module (processed EEG index): $6,000–$18,000 (£4,800–£14,400)
• Agent and gas analyser module: $4,000–$11,000 (£3,200–£8,800)
• Disposable forehead EEG sensor: $12–$28 each (£10–£22)
• Service contract: 8–14% of capital price per year, typically from year two

Margin by model

Manufacturers in medical devices have historically held gross margins around 71%, against roughly 52% for hospital supply companies, according to analysis published by CMS (CMS Health Care Industry Market Update, Medical Devices & Supplies). Capital-equipment distributors sit far lower: public filings from medical equipment distributors show gross margins in the 18% to 30% band depending on mix and period. For an anaesthesia monitoring startup the realistic planning assumptions are 55–70% gross on own-IP manufacture, 35–48% on private label, and 18–30% on pure distribution, with net margins of 8–18%, 6–12% and 4–9% respectively once regulatory maintenance and field service are loaded.

Worked example: the attach rate is the business

Take a depth-of-anaesthesia entrant that places 140 monitors into 46 US ambulatory surgery centres at an average capital price of $7,400. Capital revenue is $1.04 million. Now layer the consumable. Each monitor runs 3.2 cases per operating day across 240 operating days, and each case consumes one $19 disposable forehead sensor:

140 monitors × 3.2 cases × 240 days × $19 = $2.04 million of consumable revenue in a full year.

So by year two the consumable line is roughly twice the hardware line. At a 74% gross margin on sensors and 52% on hardware, blended gross profit is about $2.05 million on $3.08 million of revenue, a 67% blended gross margin. The hardware is a customer-acquisition cost that happens to be revenue-positive. That is the structure a Series A investor is underwriting, and it is why the sensor supply chain, not the monitor, belongs at the top of your operations section.

Run the same arithmetic without a proprietary consumable and the business looks entirely different: $1.04 million of one-off revenue against a replacement cycle of seven to ten years, with service contracts at 8–14% providing the only recurring line. Both are real businesses. Only one of them raises a venture round.

A second example for the distribution route

A regional distributor carrying two brands at a 24% blended gross margin needs roughly $4.6 million of annual turnover to cover a six-person team — two field representatives at the $157,251 average total compensation cited above, one biomedical service engineer, one tender writer and two back-office staff — plus about $340,000 of fixed overhead, and still clear a 7% net margin. Below roughly $3 million of turnover the same structure loses money, which is why most successful regional distributors in this category start with a two-person team and a service-led proposition rather than a full commercial build.

Secondary revenue lines worth modelling

• Extended warranty and planned preventive maintenance: predictable, high margin, and the main reason hospitals stay with an incumbent
• Calibration and electrical safety testing for third-party equipment already in the theatre
• Software licences for anaesthesia record integration and theatre analytics, usually per-bed or per-theatre annual
• Rental and managed-equipment contracts for ASC chains that prefer opex to capex
• Training and competency packages for theatre staff, often a tender scoring criterion rather than a revenue line in its own right

Three Business Models, Side by Side

Pick one and commit to it in the plan. Founders who describe themselves as "a manufacturer and distributor" usually mean they have not chosen, and reviewers read it that way.

A hybrid does exist and it works: distribute established brands for cash flow while developing one differentiated module behind it. If that is your plan, model the two units separately with their own cost lines and their own funding sources, and make the dependency explicit — namely that distribution gross profit is funding device development, and what happens to the development timeline if the agency is lost. Reviewers reward that honesty. See also our medical device manufacturer business plan template for the manufacturing-only variant.

Conformity: FDA, UKCA, EU MDR and CDSCO

Four jurisdictions, four separate processes. Since the UK left the EU conformity system these are no longer one workstream with local variations, and planning them as if they were is the most expensive sequencing mistake available in this category.

United States

• Class II, 510(k) premarket notification. You demonstrate substantial equivalence to a legally marketed predicate device. Approval, in the strict sense, applies to Class III via PMA and is rare here.
• Timeline. The FDA targets a 90-day review decision for the large majority of 510(k) submissions; in practice a detailed submission runs roughly 108–142 calendar days once hold time is counted, and real programmes run 6 to 18 months from prototype to clearance (510(k) process and timeline).
• Fees. $26,067 standard or $6,517 small business for the submission; $11,423 annual establishment registration (FY2026).
• Quality system. 21 CFR Part 820, now harmonised with ISO 13485 under the Quality Management System Regulation. Build it before the submission, not after.
• Standards the reviewer will expect. IEC 60601-1, 60601-1-2 (EMC), 60601-1-8 (alarm systems), 60601-2-49 (multifunction patient monitoring equipment), IEC 62304 (software lifecycle), ISO 14971 (risk management) and ISO 10993 for sensor biocompatibility.
• Small Business Determination. Apply early. The SBD is worth $19,550 on a single submission and takes weeks to obtain, so founders who skip it pay the full fee purely for being late.

United Kingdom

• UKCA marking under the UK Medical Devices Regulations 2002 as amended. A monitor carrying an alarm-bearing vital-function claim generally classifies as Class IIb, requiring a UK Approved Body.
• MHRA registration via DORS. No upfront registration fee; an annual fee of £300 per GMDN Level 2 category applies from 1 April 2026. Devices must already be CE or UKCA marked, with proof supplied in the application.
• UK Responsible Person. Mandatory for non-UK manufacturers. Budget roughly $9,000–$32,000 across three years for a Class IIb device, excluding government fees.
• NHS Supply Chain framework admission. Commercially decisive even though it is not a legal requirement. Frameworks run on multi-year cycles, so align your launch with the tender calendar.
• Clinical positioning. NICE has assessed depth-of-anaesthesia monitors including BIS, E-Entropy and Narcotrend as a category, so UK buyers will expect your evidence to be framed against that assessment rather than against marketing claims (NICE diagnostics guidance DG6).

European Union

• EU MDR 2017/745, Class IIb via a notified body. Total cost from application to first certificate typically EUR 50,000–150,000 for an SME.
• Component fees within that: application EUR 2,760–3,500, initial QMS audit EUR 9,200–18,000, technical documentation assessment EUR 13,000–32,300, clinical evaluation assessment EUR 2,000–6,100.
• Timeline. 12 to 30 months from first notified-body contact to certificate, driven largely by notified-body queue length and documentation quality (EU MDR notified body guide, 2026).
• Deadline to note. Class IIb non-implantable devices face a 31 December 2028 MDR certification deadline, which is already shaping notified-body capacity.

India

• CDSCO Class C for patient physiologic monitoring systems including anaesthesia monitors.
• MD-15 import licence: USD 3,000 per site plus USD 1,500 per device, with an Indian Authorised Agent holding a wholesale drug licence required to file.
• MD-9 manufacturing licence applies instead if you manufacture domestically, which several entrants do to serve price-sensitive private hospital chains.
• Why it belongs in a seed-stage plan: India is one of the few markets where a sub-$4,000 monitor is a strategic product rather than a discount, and CDSCO costs are an order of magnitude below EU MDR.

The reimbursement question, answered properly

There is no separate payment code to build a US revenue model on. Depth-of-anaesthesia monitoring is generally treated as part of the anaesthesia service and the facility payment rather than attracting standalone reimbursement, and NICE frames the UK case around awareness and recovery outcomes rather than a separate tariff. That has one direct consequence for your plan: your buyer is the facility's capital committee, so the value case has to be built from theatre turnover time, recovery-room length of stay, drug consumption and risk reduction. Write that business case into the sales section explicitly. Device plans that assume a code exists get found out in the first clinical diligence call.

Seven Mistakes That Sink the Forecast

These are the recurring failures we see in anaesthesia monitoring plans that arrive for review, roughly in order of how much money they cost.

1. Treating the FDA user fee as the regulatory budget

The $26,067 FY2026 submission fee is a rounding error against a realistic clearance programme. Once verification testing, quality system build, clinical and usability evidence and consultant time are loaded, the fee is around 2% of the total. Plans that show a $30,000 regulatory line signal to a reviewer that the founder has not spoken to a test house yet.

2. A hardware-only revenue line

If your monitor has a proprietary consumable, model it. If it does not, say so and explain what produces recurring revenue instead — service contracts, software licences or a managed equipment contract. What does not work is a forecast that shows unit sales growing linearly forever with no replacement-cycle logic and no recurring line at all.

3. Assuming a reimbursement code exists

Covered above, and worth repeating because it reshapes the whole go-to-market section. The purchase decision sits with a facility capital committee, which means your sales cycle is quarterly budget cycles, group purchasing organisation contracts and framework agreements, not clinician preference alone.

4. Selecting the predicate device late

Predicate choice determines the comparison claims, which determines the test matrix, which determines the bill of materials. Founders who freeze the design first and then look for a predicate routinely discover they have engineered a device that is substantially equivalent to nothing on the market. Name the predicate in the plan. If you cannot, that is itself the finding.

5. Planning UK and EU entry as one workstream

UKCA and EU MDR are separate conformity routes with separate bodies, separate fee schedules and separate queues. A single line reading "CE/UKCA marking: £60,000" is a tell. Separate them, sequence them, and decide which one you need first based on where your first twenty customers actually are.

6. Leaving alarm-system conformity until EMC testing

IEC 60601-1-8 governs alarm priority, audible and visual signalling, and the alarm condition logic itself. It is architectural, not cosmetic. Teams that discover it during pre-compliance testing typically face a firmware rewrite and a three to five month slip. Design to it from the first sprint.

7. Pricing against the incumbent list price

Undercutting GE HealthCare or Drägerwerk on sticker price misreads the buying decision. The incumbent's advantage is the installed base, the existing service contract, trained staff and integration with the anaesthesia record system. Switching cost, not list price, is what you are competing against, and the usual winning angles are a narrower product that fits an underserved setting, a service response time the incumbent cannot match locally, or an opex model for ASC chains that do not want capital on the balance sheet.

Terms Your Investor Will Expect You to Use Correctly

Precision here is a credibility signal. Diligence calls in this category are usually run by someone with clinical or regulatory background.

• Processed EEG index. A single dimensionless number derived from a frontal EEG signal, intended to track hypnotic depth. BIS and entropy both produce comparable index values, with roughly 40 to 60 regarded as a surgical range.
• BIS versus entropy. BIS applies several models depending on the phase of anaesthesia and filters out the electromyographic component. Entropy uses one model and treats the EMG signal as part of the measurement. Clinically comparable; commercially distinct, because each locks the customer into its own sensor.
• Capnography and end-tidal CO2. Measurement of exhaled carbon dioxide, the standard confirmation that ventilation is adequate and the airway is intact. Related equipment is covered in our capnography equipment business plan template.
• Agent monitoring. Measurement of inspired and expired volatile anaesthetic agent concentration plus nitrous oxide, usually alongside ETCO2, FiCO2, respiratory rate, SpO2 and pulse rate on the same module.
• Neuromuscular transmission monitoring. Quantification of residual paralysis, increasingly expected as standard of care and a growth segment within the broader category.
• Predicate device. The legally marketed device your 510(k) claims substantial equivalence to. It defines your testing obligations.
• Legal manufacturer. The entity whose name is on the label and who holds the regulatory obligations, which is not necessarily the entity that physically builds the device. Central to any ODM arrangement.
• Attach rate. Consumables consumed per installed device per period. The single most load-bearing assumption in a monitoring-device forecast.
• UKRP. UK Responsible Person — the UK-established entity a non-UK manufacturer must appoint to register devices and liaise with the MHRA.

Sample Business Plan Preview

Here is an extract from an anaesthesia monitoring device plan written by our team, so you can see the level of specificity we work at:

What's in the Template

Every Avvale business plan template includes these sections, pre-structured for your industry:

• Executive Summary — your device, your regulatory route and your capital ask in a page an investor reads in 60 seconds
• Company Overview — legal structure, who holds the legal manufacturer role, founding story and IP position
• Industry Analysis — market sizing with the definition stated, vendor share, and an installed-base bottom-up serviceable market
• Customer Analysis — hospital theatres, ambulatory surgery centres, dental and office-based sedation, veterinary theatres, and how each buys
• Competitor Analysis — positioning against workstation vendors, algorithm specialists and cost-led regional brands, with switching cost quantified
• Regulatory Plan — predicate, classification, test matrix, jurisdiction sequence and costed fee schedule
• Marketing Plan — evaluation-unit strategy, clinical champion development, GPO and framework route, and the capital-committee business case
• Operations Plan — contract manufacturing, sensor supply chain, field service network and calibration obligations
• Management Team — founder bios, clinical advisory board and the regulatory and quality hires a reviewer expects to see named

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis and startup capital requirements — with hardware and consumable revenue modelled as separate drivers, which is the part most generic templates get wrong for this category. For a broader starting point, see the free business plan template hub, or the ambulatory surgery center business plan template if you are modelling the buyer rather than the supplier.

Frequently Asked Questions